Bayer AG Sponsored ADR (BAYRY)
Bayer applies for third indication of Nubeqa in EU
Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy.
Bayer must pay $78 mln in latest Roundup cancer trial, jury finds
Bayer must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday.
Bayer shares down 7% after U.S. court says it will review Monsanto case
Shares of German life sciences company Bayer fell more than 7% on Wednesday, after a U.S. court said it would review a case alleging that exposure products made by the company's Monsanto unit harmed individuals. The Washington Supreme Court this week accepted a review of a litigation against the German company over alleged polychlorinated biphenyls (PCBs) exposure at the Sky Valley Education Center.
Bayer Reports Positive Safety Data on Parkinson's Disease Drug
BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.
MustGrow Biologics CEO discusses commercial expansion, Bayer partnership - ICYMI
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson joined Proactive to chat about the company's transition to commercialization from its R&D focus. He noted the commercialization of its biofertility product TerraSante, which has gained momentum in key US states.
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Bayer (BAYRY) Moves to Buy: Rationale Behind the Upgrade
Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
Bayer: Speculative Value Beyond Litigation Pressures
Bayer's Q2 2024 results were mixed, with strong Pharmaceuticals performance offsetting challenges in Crop Science and stable Consumer Health results. The reaffirmation of full-year guidance and a significant legal win in the "Schaffner vs. Monsanto" case offer some reassurance to investors. Under all the litigation noise, Bayer is still a strong, innovative business, with potential in both agriculture and pharma.
Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study
BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.
Bayer Initiates Late-Stage Study on Investigational NSCLC Drug
BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.
Bayer, NextRNA to Develop Therapeutics Targeting Oncology
BAYRY collaborates with NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology.
